全文获取类型
收费全文 | 320篇 |
免费 | 24篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
基础医学 | 19篇 |
临床医学 | 25篇 |
内科学 | 53篇 |
特种医学 | 4篇 |
外科学 | 210篇 |
综合类 | 4篇 |
预防医学 | 11篇 |
药学 | 2篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 13篇 |
2020年 | 7篇 |
2019年 | 9篇 |
2018年 | 14篇 |
2017年 | 14篇 |
2016年 | 4篇 |
2015年 | 9篇 |
2014年 | 14篇 |
2013年 | 14篇 |
2012年 | 37篇 |
2011年 | 35篇 |
2010年 | 12篇 |
2009年 | 13篇 |
2008年 | 12篇 |
2007年 | 12篇 |
2006年 | 14篇 |
2005年 | 18篇 |
2004年 | 17篇 |
2003年 | 17篇 |
2002年 | 15篇 |
2001年 | 12篇 |
2000年 | 11篇 |
1999年 | 5篇 |
1998年 | 1篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 2篇 |
1985年 | 1篇 |
排序方式: 共有344条查询结果,搜索用时 15 毫秒
41.
M. V. Rao N. Singh I. Master A. Lutckii S. Keshavjee J. Andersson A. Zumla M. Maeurer 《Journal of internal medicine》2015,277(4):388-405
The first cases of totally drug‐resistant (TDR) tuberculosis (TB) were reported in Italy 10 years ago; more recently, cases have also been reported in Iran, India and South Africa. Although there is no consensus on terminology, it is most commonly described as ‘resistance to all first‐ and second‐line drugs used to treat TB’. Mycobacterium tuberculosis (M.tb) acquires drug resistance mutations in a sequential fashion under suboptimal drug pressure due to monotherapy, inadequate dosing, treatment interruptions and drug interactions. The treatment of TDR‐TB includes antibiotics with disputed or minimal effectiveness against M.tb, and the fatality rate is high. Comorbidities such as diabetes and infection with human immunodeficiency virus further impact on TB treatment options and survival rates. Several new drug candidates with novel modes of action are under late‐stage clinical evaluation (e.g. delamanid, bedaquiline, SQ109 and sutezolid). ‘Repurposed’ antibiotics have also recently been included in the treatment of extensively drug resistant TB. However, because of mutations in M.tb, drugs will not provide a cure for TB in the long term. Adjunct TB therapies, including therapeutic vaccines, vitamin supplementation and/or repurposing of drugs targeting biologically and clinically relevant molecular pathways, may achieve better clinical outcomes in combination with standard chemotherapy. Here, we review broader perspectives of drug resistance in TB and potential adjunct treatment options. 相似文献
42.
C. H. Wigfield M. Cypel J. Yeung T. Waddell C. Alex C. Johnson S. Keshavjee R. B. Love 《American journal of transplantation》2012,12(10):2838-2844
A recent clinical trial provided evidence that ex vivo lung perfusion (EVLP) results in optimized human donor lungs for transplantation. Excellent recipient outcomes were documented after 4 h of normothermic perfusion. We report a clinical case utilizing remote EVLP to assess and improve function of initially otherwise unacceptable injured donor lungs followed by transportation and subsequent bilateral lung transplantation in a patient with virally induced refractory respiratory failure supported with extracorporeal membrane oxygenation. This is the first lung transplantation with the application of remote EVLP, wherein the donor lungs were transported from the donor hospital to a center for EVLP and then transported to another hospital for transplantation. It is also the first case of lung transplantation in the United States utilizing EVLP for functional optimization leading to successful transplantation. Organ procurement data, EVLP assessment, and the pre‐ and postoperative course of the recipient are presented. The available evidence supporting EVLP, the humanitarian and cooperative utilization of lungs otherwise discarded, are discussed. 相似文献
43.
M‐L. Luong S. M. Hosseini‐Moghaddam L. G. Singer C. Chaparro S. Azad N. Lazar P. C. Boutros S. Keshavjee C. Rotstein S. Husain 《American journal of transplantation》2012,12(7):1929-1935
Voriconazole is commonly used for prophylaxis and treatment of invasive aspergillosis in lung transplant recipients. However, the use of voriconazole may at times be limited by the development of hepatotoxicity. Our goal is to determine predictors of voriconazole‐associated hepatotoxicity in lung transplant recipients. We conducted a single center retrospective cohort study of lung transplant recipients from 2006 to 2010 who received voriconazole therapy. We compared characteristics of patients who developed hepatotoxicity and those who did not. One hundred five lung transplant recipients received voriconazole. Hepatotoxicity occurred in 51% (54/105) of patients and lead to discontinuation in 34% (36/105). In univariate analysis, age less than 40 years, cystic fibrosis, use of azathioprine, history of liver disease and early initiation of voriconazole were associated with hepatotoxicity. In multivariable logistic regression analysis, perioperative initiation of voriconazole (within 30 days of transplantation) was independently associated with hepatotoxicity (OR 4.37, 95% CI: 1.53–12.43, p = 0.006). The five risk factors identified in the univariate analysis were used to build a K‐nearest neighbor algorithm predictive model for hepatotoxicity. This model predicted hepatotoxicity with an accuracy of 70%. Voriconazole therapy initiated within the first 30 days of transplantation is associated with a greater risk of developing hepatotoxicity. 相似文献
44.
45.
46.
Raviv Y D'Ovidio F Pierre A Chaparro C Freeman M Keshavjee S Singer LG 《Clinical transplantation》2012,26(1):133-142
The main cause of late morbidity and mortality after lung transplantation is bronchiolitis obliterans syndrome (BOS). This study assesses the prevalence of gastroparesis among lung-transplant recipients and its association with BOS. The files of 139 patients who underwent nuclear gastric emptying studies before and/or three and 12 months after lung transplantation were reviewed, and the correlation of gastric emptying time (GET) at each time point with the occurrence of acute rejection or BOS (stage 0p or higher) was evaluated. Delayed gastric emptying (DGE; t(1/2) > 90 min) was documented in 50% of patients before transplantation - 74% at three months and 63% at 12 months. Median pre-transplant t(1/2) was 108 min in patients who acquired BOS and 77 min in BOS-free patients (p = 0.022). Among patients with pre-transplant DGE, 58% were BOS-free at 24 months post-operatively and 37% at 36 months; corresponding rates in patients with normal motility were 78% and 63% (p = 0.084). On multiple regression analysis adjusting for other measures of upper gastrointestinal dysfunction, GET before or three months after transplantation was significantly associated with BOS (OR 1.05 [95% CI 1.01-1.09] and OR 1.001 [1.001-1.005] per minute t(1/2)). Gastroparesis is common in lung-transplant recipients and associated with the development of BOS. 相似文献
47.
48.
49.
50.
In the case of the thymus gland, the most common indications for resection are myasthenia gravis or thymoma. The consistency and appearance of the thymus gland make it difficult at times to discern from mediastinal fatty tissues. Having a clear understanding of the anatomy and the relationship of the gland to adjacent structures is important. 相似文献